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Abstract
Background: It is well known that epigenetic modifications play an important role in controlling the regulation of
gene expression during the development. Our previous studies have demonstrated that the expression of fetal
troponin I gene (also called slow skeletal troponin I, ssTnI) is predominated in the fetal stage, reduced after birth
and disappeared in the adulthood. The mechanism underlying the developmentally related ssTnI gene regulation
is not clear. In this study, we have explored the epigenetic role of DNA methylation in the regulation of ssTnI
expression in the heart during the development.
Results: The DNA methylation levels of CpG island and CpG dinucleotides region were detected using methylation
specific PCR (MSP) and bisulfite sequence PCR (BSP) in 2000 bp upstream and 100 bp upstream of ssTnI gene
promoter. Real time RT-PCR and Western blot were used to detect ssTnI mRNA and protein expression levels. We
found that DNA methylation levels of the CpG dinucleotides region in ssTnI gene promoter were increased with
the development, corresponding to a decreased expression of ssTnI gene in mouse heart. However the DNA
methylation levels of CpG islands in this gene were not changed during the development. Application of a
methylation inhibitor, 5-Azacytidine, in cultured myocardial cells partially prevented the decline of ssTnI expression.
Conclusion: Our results indicate that DNA methylation, as an epigenetic intervention, plays a role in the regulation
of the fetal TnI gene expression in the heat during the development.
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Background
Sarcomere protein, troponin, is located on the thin fila-
ment of myocardial cells and plays an essential role in
regulating Ca2+-activated tension of striated muscles.
Troponin component contains three isoforms: troponin
T (TnT), binding to tropomyosion forming troponin-
tropomyosion complex, troponin C (TnC), binding to
Ca2+ to produce a conformational change in TnT, and
troponin I (TnI), an inhibitory subunit binding to actin-
tropomyosion and regulating muscles contraction [1].
There are at least two developmentally regulated TnI
isoforms in the heart: the slow skeletal TnI (ssTnI) that
is expressed in the fetal heart and the cardiac TnI (cTnI)
that is predominately expressed in adult hearts [1–3].
TnI isoform switching is common in animals and hu-
man, and it is a good model to investigate the regulation
of cardiac proteins in the development [4].
It is clinically important to clarify the regulation of TnI
expression, because many cardiomyopathy and heart dis-
eases are associated with abnormal TnI protein expression
leading to diastolic dysfunction and heart failure [5–7]. In
our previous studies, we have demonstrated that ssTnI ex-
pression in heart is partially regulated by thyroid hormone
during the heart development [8, 9]. And we have also
cloned mouse ssTnI gene with upstream promoters and
revealed several regions and domains on the promoters
critically to ssTnI gene expression, such as TnI slow up-
stream regulatory elements (SURE), Yin Yang 1 factor
(YY1), proximal 300 bp upstream region and the first
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intron of ssTnI gene [10–13]. However, the mechanisms
of ssTnI down-regulation and finally shut down in the
heart after birth is still not clear.
DNA methylation is one of epigenetic modifications
and many studies have showed that DNA methylation
plays an important role in gene expression, genomic im-
printing, X-chromosome inactivation and chromatin
structure changes [14–16]. DNA methylation occurs on
position 5 of cytosine by the covalent modification of a
methyl group, creating 5-methylcytosine, which is pref-
erentially found in CpG dinucleotides [17]. The “CpG” is
shorthand for “-C-phosphate-G-”, which is cytosine and
guanine separated by only one phosphate. CpG island is
a region with high frequency of CpG sites (GC percent-
age is greater than 50 % in a region over 200 bp). In
addition, some CpG sites that are in a short distance
from CpG island are called CpG island sites (or CpG
shore), which also play an important role in regulating
gene expression [18]. The methylation of CpG dinucleo-
tides in promoter of genes always leads to a transcrip-
tional inactivation. Some studies have shown that
different levels or patterns of cytosine methylation are
found in various tissues or in different functional regions
of the same tissue [19–21]. Our previous study has
shown that epigenetic modification may regulate ssTnI
expression during heart development, especially through
histone acetylation and histone methylation [22]. How-
ever, the role of DNA methylation in the regulation of
ssTnI gene expression is still unknown. In the present
study, we have measured the levels of DNA methylation
in critical domains of ssTnI genes to determine the role of
epigenetic regulation on this gene expression. Further-
more, a DNA methyltransferase inhibitor, 5-azacytidine
has been applied to myocardial cells to confirm the DNA
methylation mediated ssTnI gene expression in the heart.
Our results indicate that DNA methylation plays an im-
portant role in the regulation of ssTnI expression in the
heart during the development.
Methods
Experimental animals
All animal procedures were approved by the Animal
Care and Use Committee at the Chongqing Medical
University. Adult wild type KM mice (body weight of
18–22 g) were purchased from Chongqing Medical
University Animal Center. Upon arrival, breeder mice
were separately housed and acclimated for at least one
week before mating began. The mice were maintained
on a reverse 12 h light-dark cycle (light 19:00–07:00)
and provided with laboratory chow and water ad libitum.
Two females were placed with one male for two hours
between 08:00 and 10:00. When a vaginal plug was de-
tected after mating period, which was designated as em-
bryonic 0.5 day (E0.5). E14.5, E17.5 pregnant mice,
postnatal day 1, day 7, day 14 and adult mice were sacri-
ficed using CO2 gas. Embryonic and postnatal heart
tissue were collected and frozen at −80 °C until use.
Culture of mouse myocardial cells
Primary cultures of myocardial cells were performed as
described previously [23]. Cardiac myocytes were col-
lected from the mice of postnatal day 14 mice. The cells
were randomly divided into two groups, the untreated
control group (treated with nothing), 5-azacytidine
group (5 μM 5-azacytidine). 5-azacytidine (Sigma, Santa
Clara, California, USA) was dissolved in tissue culture
medium to make a stock solution and stored in −20 °C.
After treated with 5-azacytidine for 24 h, cells were col-
lected and stock at −80 °C for further analyses.
Real-Time RT-PCR
The real-time PCR was carried out as described previously
[10, 11]. The data were analyzed using 2-[△Ct (target) - △Ct
(input)] method [24] following the manufacture’s instruc-
tion. The primers for PCR amplification: ssTnI forwarding
primer: 5′-CTCCACGAGGACTAAACTAGGC-3′, revers-
ing primer: 5′-CTTGGATTTCCTCTCAACTTCC-3′. β-
actin forwarding primer: 5′-CACACCCGCCACCAG
TTCG-3′, reversing primer : 5′-GTCCTTCTGACCCAT
TCCCACC-3′.
Western blot
Western blotting assays for ssTnI were performed as
previously describe [8]. An anti-TnI monoclonal anti-
body (TnI-1) that recognized mouse ssTnI was used at a
dilution of 1:10,000. The immune-reactive protein bands
were visualized with Chemiluminescent Luminol
Reagent (Merck Millipore, USA). After scanning, protein
bands were analyzed with Quantity One Version 4.4
software (Bio-Rad, CA, USA).
Methylation specific PCR (MSP)
Genomic DNA was isolated from ventricular tissue and
myocytes cells using a TIANamp Genomic DNA Kit
(Tiangen, Beijing, China). DNA methylation of ssTnI
promoter CpG islands and CpG dinucleotides region
were detected by methylation specific PCR (MSP) using
2 × Power Taq PCR MasterMix (Bioteck, Beijing, China)
in a final volume of 25 μl. Bisulfite treatment of unmethy-
lated DNA converted cytosines to uracils at CpG dinucle-
otides. However, methylated cytosines were not converted.
Specific primers were designed to amplify the target re-
gions of interest with unmethylated CpG dinucleotides by
detecting uracils and methylated CpG dinucleotides by
detecting cytosines. Primer were designed using MethPri-
mer software (http://www.urogene.org/cgi-bin/methpri-
mer/methprimer.cgi). M pair was indicated methylation of
CpG sites within the primer sequences, U pair indicated
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no methylation, and both pairs indicated a partial
methylation: ssTnI CpG island forwarding M primer:
5′-TTGGGGTAGTAGGGTAGAGATATTC-3′, reversing
M primer: 5′-TTCTCTTATTCTAAATTCCAACGTC-3′.
Forwarding U primer: 5′-TTGGGGTAGTAGGGTAGAG
ATATTT-3′, reversing U primer: 5′-TTCTCTTATTCT
AAATTCCAACATC-3′. ssTnI CpG dinucleotides region
forwarding M primer: 5′-ACGGTAGTATATATTTGTT
TTGCGA-3′, reversing M primer: 5′-ACTATAAAAACC
GTAACCTCCGAC-3′. Forwading U primer: 5′-ATGGT
AGTATATATTTGTTTTGTGA-3′, reversing U primer:
5′-AACTATAAAAACCATAACCTCCAAC-3′.
Bisulfite Sequencing PCR (BSP)
To verify the methylation level of these heart tissues and
myocytes cells, bisulfite sequencing PCR (BSP) was used.
DNA was first modified by treatment with sodium bisul-
fite to convert all ‘C’s to uracil residues except 5 mCs.
Then bisulfite-modified DNA were amplified by PCR,
which performed in a RT-PCR instrument (MJ Mini
Personal Thermal Cycler, BIO-RAD) using 2 × Power
Taq PCR MasterMix (Bioteck, Beijing, China) under the
Touch-down program: 95 °C for 3 mins, followed by
9 cycles of 94 °C for 30 s, 60 °C for 30 s (decrease 1 °C
per cycle), 72 °C for 1 min, then followed by 40 cycles of
94 °C for 30 s, 50 °C for 30 s, 72 °C for 1 min, and final
extension 72 °C for 10 mins. The BSP primers were de-
signed using MethPrimer: ssTnI CpG island forwarding pri-
mer: 5′-TGGGGTTAGAGTGTAAAGTTAATATTG-3′,
reversing primer: 5′-TATAACTCCAAACACCCATCTC
TCT-3′. ssTnI CpG dinucleotides region forwarding
primer: 5′-TTGGTTTTTAAGTTTGTGGTTTATA-3′, re-
versing primer: 5′-CTAAACTAACCTAAACCTCACCAC
AA-3′. The resulted PCR product were used to direct se-
quencing at INVITROGEN (Shanghai, China) to examine
bisulfite conversion rate for different time heart tissue [25].
Moreover, the PCR product were recovered by TIANgel
Midi Purification Kit (TIANGEN, Beijing, China) after veri-
fication in a 2 % agarose gel. Then the purified DNA was li-
gated into the vector pGM-T by pGM-T Cloning Kit with
Competent Cell (TIANGEN, Beijing, China) and trans-
formed into E. coli strain TOP10. Sequence determinations
were carried out at SANGON (Shanghai, China) [14].
Statistics
All RT-PCR and Western blot data are showed as mean ±
SD. BSP sequences data are analyzed using software from
BiQ Analyzer (http://biq-analyzer.bioinf.mpi-inf.mpg.de/)
to calculate the level of DNA methylation (methylation
level =methylated CpG dinucleotides/total CpG dinucleo-
tides). Statistical analysis was carried out by SPSS 19.0
using ANOVA and Student’s t-test to determine stat-
istical significance. The criteria for significance were
defined as p <0.05.
Results
The time course of the expression of ssTnI mRNA and
protein in mouse heart during embryonic day 14.5 to
adult is shown in Fig. 1. The highest expression level of
ssTnI mRNA was observed in embryonic day 14.5 and
17.5. The expression of ssTnI was declined gradually
after birth. In the adult heart, ssTnI expression was
barely detected (Fig. 1a). The time course of ssTnI pro-
tein levels (Fig. 1b and c) was similar to that of ssTnI
mRNA during the heart development, which is consist-
ent with what we reported previously [8].
The MethPrimer was used to predict CpG islands and
CpG dinucleotides regions in ssTnI gene promoter. Only
one CpG island was found in the upstream of ssTnI
gene, which is about 2000 bp away from the transcrip-
tion start site (TSS). However, various CpG dinucleo-
tides were found in different domains of the ssTnI gene
promoter. One CpG dinucleotides region containing 5
CpG sites was found in about 100 bp from TSS on ssTnI
gene. MSP assays were performed to determine DNA
methylation on ssTnI gene promoter. The DNA methy-
lation of CpG island in ssTnI was shown in Fig. 2a, indi-
cating that all of CpG islands were fully methylated in
all of the time points tested during the heart develop-
ment. However, the methylation of CpG dinucleotides
region was different, which showed that the CpG sites
was unmethylated in embryonic day 14.5, 17.5 and new-
born, but after birth on postnatal day 7 and 14, methyla-
tion occurred on these sites and reached a peak level of
methylation in adulthood (Fig. 2b). The gradual methyla-
tion of these sites on ssTnI gene shortly after birth is
corresponding to a gradual decline of the ssTnI gene ex-
pression in the heart during the same time course.
Bisulfite sequence PCR (BSP) assays were carried out
to confirm the data obtained from MSP assays. The data
from BSP showed that DNA methylation in CpG island
of ssTnI gene was not significantly changed during heart
development, however, the DNA methylation levels in
CpG dinucleotides regions showed that these sites were
not methylated during the embryonic stage and even at
newborn in the heart and methylation started on these
site shortly after the birth, which are consistent with the
results from MSP assays.
5-azacytidine, a methylation inhibitor, was applied to
14-day-old myocardial cells to see whether ssTnI expres-
sion increases after the inhibition of ssTnI gene methyla-
tion. The expression of mRNA in myocardial cells that
were prior treated with 5 μM 5-azacytidine for 24 h was
significantly increased compared to that of the untreated
control group (Fig. 3). The MSP data showed that 5-
azacytidine could reduce DNA methylation in the CpG di-
nucleotides regions, while the methylation status of CpG
island was not changed compared to the untreated control
group (Fig. 4a and c). The BSP data in myocardial cells
Xu et al. Journal of Biomedical Science  (2015) 22:88 Page 3 of 7
indicated that 5-azacytidine could reduce the methylation
level of CpG dinucleotides region in ssTnI promoter com-
pared to the untreated control group (Fig. 4b and d).
Discussion
Troponin I is not only a structural protein but also
an important regulatory protein that controls cardiac
muscle contraction and relaxation. The ischemia and
oxidative stress may cause cardiac muscle cell dam-
ages such as cell death, and then, the troponin pro-
tein is released from myocardial cells into blood.
Therefore, troponin has become a critical myocardial
marker to estimate the cardiac damages [26, 27].
Troponin I isoform switching during heart develop-
ment was discovered almost three decades ago [28].
But the mechanisms of the fetal TnI (ssTnI) gene in-
activation soon after birth are still unclear. The devel-
opmental switch from fetal to adult troponin I is
found in lower and higher animals, and even in hu-
man beings. For this reason, TnI family has become a
good model to investigate the regulation of cardiac
proteins during heart development [4]. Re-expression
of many fetal protein genes normally observed in fetal
heart may occur in several pathological conditions
such as cardiac hypertrophy and heart failure [29].
However no ssTnI re-expression is observed even in
severe pathological conditions or in the heart at the
end stage [9, 30]. We have cloned and characterized
mouse ssTnI gene and our previous studies have
showed that ssTnI gene was gradually shut down
15 days after birth in mouse hearts. Several important
regulatory domains and elements on ssTnI promoters
have been identified, such as SURE, a specific domain in
upstream part of ssTnI gene, and one internal regulatory
element (IRE) in the first intron region [4, 10–13]. We
also predicted some transcription factors binding to the
100 bp upstream of ssTnI gene promoter, for example,
specificity protein 1 (Sp1), myogenic differentiation
(MyoD) and myocyte enhancer factor-2 (MEF-2). In
addition, we have also found that the thyroid hormone
could partially regulate the ssTnI gene expression in the
developing mouse heart [9].
Recently, epigenetics, which is defined as the inter-
action of DNA methylation, histone modification and
expression of noncoding RNAs, has been demonstrated
to play an important role in the regulation of gene ex-
pression during the development [31–33]. Early studies
have showed that methylation and demethylation play a
role on regulation of gene expression during develop-
ment, and there is an inverse correlation between DNA
methylation and gene expression [33–35]. In mammalian
genome, approximately 70 % of CpG are methylated
[36], on the other hand, unmethylated CpG are grouped
in clusters called “CpG island” in gene promoter regula-
tory regions. Interestingly, some methylation alterations
do not occur in CpG island but in CpG dinucleotides
(called CpG shores), and methylation on CpG island
shores is strongly related to gene expression [18]. Our
Fig. 1 Time course of ssTnI mRNA and protein expression in the heart
during development. a Expression of ssTnI mRNA is maintained at a
high level until newborn. After birth, ssTnI expression in the heart is
decreased. b Representative immunoblot of ssTnI protein content in
mouse heart during development. c Summary of the ssTnI protein
content in the mouse heart during development. The ssTnI protein
expression in the heart is consistent with the mRNA expression pattern
observed in the same heart. ANOVA showed a significantly different
the expression levels in experimental groups, and asterisk indicates
p < 0.05 in two groups comparison by t test between E14.5 group and
other groups. E14.5: embryonic day 14.5, E17.5: embryonic day 17.5,
NB: newborn, P7: postnatal day 7, P14: postnatal day 14
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previous study has shown that histone modification,
such as acetylation or methylation, may affect ssTnI ex-
pression during heart development [22]. However, little
is known about the effect of DNA methylation on the
regulation of ssTnI gene expression during heart devel-
opment. In this study, our results have demonstrated
that the DNA methylation on CpG dinucleotides regions
of ssTnI promoter, located on 100 bp upstream from
TSS, is gradually increased during heart development,
but the level of DNA methylation on CpG island of
ssTnI promoter does not change, suggesting the DNA
methylation on CpG dinucleotides regions is associated
with a down regulation of ssTnI gene expression in the
heart. This CpG dinucleotides region is located in
100 bp upstream of the ssTnI TSS, which has been
identified to be able to bind with several critical tran-
scription factors, such as Sp1, MyoD and MEF-2. The
enhanced methylation of this domain may inhibit the
function of transcription factors and affect gene ex-
pression. Whereas the methylation of CpG island on
ssTnI promoters is stable without any significant
change at the different time points during the devel-
opment, indicating that the CpG islands may not be
the targets for regulation of ssTnI gene expression
during heart development.
5′-azacytidine is a DNA methyl-transferase inhibitor
that can reverse the DNA hypermethylation and rees-
tablish gene expression [37, 38]. In this study, in
order to confirm the methylation regulatory mechan-
ism, 5-azacytidine has been used to treat myocardial
Fig. 2 DNA methylation of CpG islands and CpG dinucleotide regions in ssTnI gene promoter. a DNA methylation of CpG islands in ssTnI
promoter. The CpG island is fully methylated in the cardiac tissues at different time points during development. b CpG dinucleotides methylation
in -100 bp region away from ssTnI transcription starting site (TSS). In E14.5, E17.5 and NB, the CpG dinucleotides are unmethylated, but in P7, P14,
those regions show a partial methylation. In adult, it is fully methylated. M, methylated; U, unmethylated. c The ssTnI CpG island methylation
levels observed in mouse cardiac tissues during development. Methylation on ssTnI CpG islands is stably maintained in a high level during heart
development. d CpG dinucleotides methylation levels observed in ssTnI promoter -100 bp. The bisulfite sequence data show that an altered DNA
methylation level of CpG site in ssTnI -100 bp region during heart development. ANOVA analyses indicate a significantly different in methylation
levels among various experimental groups, and *p < 0.05 indicates a statistical difference in two groups compared using t test
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cells to see whether ssTnI expression can be resumed
by 5-azacytidine. Our results indicate that expression of
ssTnI mRNA is increased in myocardial cells after treat-
ment with 5-azacytidine (5 μM). The MSP and BSP data
have shown that the increased DNA methylation in dinu-
cleotides region located in -100 bp of ssTnI promoter is
significantly reduced in myocardial cells treated with 5-
azacytidine, while the CpG island was not influenced. Our
study has demonstrated for the first time that methylation
on the CpG dinucleotides region, not the CpG island, may
play an important role in regulation of ssTnI gene expres-
sion during heart development.
Conclusion
Our results indicate that DNA methylation occurs on
CpG dinucleotides region, locating at -100 bp of ssTnI
gene promoter, can cause the corresponding changes in
ssTnI gene expression. But the methylation of CpG island
on ssTnI gene promoter may not be critical in the regula-
tion of ssTnI gene expression during heart development.
In addition, DNA methylation inhibitor 5-azacytidine can
increase ssTnI mRNA expression by reducing methylation
on CpG dinucleotides region in ssTnI gene promoter.
These data indicate that the epigenetic modification is in-
volved in regulation of myofibril gene expression during
heart development in mice.
Fig. 3 Expression of ssTnI mRNA in myocardial cells with or
without treatment of 5-azacytidine. Myocardial cells were isolated
from the heart at age of 14 days. One group was treated with
5 μM 5-azacytidine for 24 h, and another group was treated with
medium without 5-azacytidine as controls. The quantitative
RT-PCR data show a significantly increase of ssTnI mRNA in the
cells treated with 5 μM 5-azacytidine. *p < 0.05 indicates a
statistical difference in two groups compared using t test
Fig. 4 DNA methylation of CpG islands and CpG dinucleotide regions in myocardial cells with or without treatment of 5-azacytidine. Myocardial
cells were isolated from 14-day-old mouse hearts. One group was treated with 5-azacytidine and another group was treated with medium
without 5-azacytidine as the control. a MSP results of CpG island methylation in ssTnI promoter. The CpG islands are methylated both in blank
and 5 μM 5-azacytidine treated groups. b MSP results of CpG dinucleotide region methylation in ssTnI promoter region -100 bp away from ssTnI
TSS. The MSP data show that the methylation level on CpG sites in -100 bp of ssTnI TSS is reduced in cells treated with 5-azacytidine. M, methylated;
U, unmethylated. c Summary of the Bisulfite sequence data of methylation on CpG island in ssTnI promoter, indicating that there is no methylation
change either in cells treated with 5-azacytidine or in control cells. d Summary of the Bisulfite sequence data of methylation on CpG dinucleotide
region in ssTnI promoter area -100 bp away from the ssTnI TSS. The results show a significant decrease of DNA methylation on these regions in the
cells treated with 5-azacytidine. *p< 0.05
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